Tariffs caused Glendale-based Weyco Group to pay $16 million in 2025

Weyco Group, a Glendale-based shoe manufacturer currently suing the Trump administration over its tariff policies, reported paying $16 million in tariffs in 2025. This cost impacted their profitability, with the company reporting $23.1 million in 2025 earnings, a 24% decrease from the previous year's $30.3 million.

Original reporting
Milwaukee Journal Sentinel · Ricardo Torres
Published Mar 5, 2026, 11:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 5, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tariffs caused Glendale-based Weyco Group to pay $16 million in 2025 — source image
Decision brief

The 30-second read

$WEYSBearishMed
01

Why it matters

Tariffs have directly increased costs, reducing profitability and negatively impacting stock sentiment.

02

Market read

The news has immediate relevance for Weyco Group and its sector, with potential ripple effects in manufacturing and retail sectors.

03

What to watch

Potential long-term benefits from tariffs, such as reduced import competition or strategic realignments.

Timing: Immediate, as the news is recent and impacts current earnings.

Background

Weyco Group is a footwear manufacturer affected by tariffs imposed during the Trump administration, leading to increased costs.

Company-level read

Ticker impact

$WEYSBearishHigh confidence
Context

High relevance due to direct impact on company's earnings and sentiment.

Expected impact

Moderate decline expected in the near term, with potential further downside if tariffs persist.

Evidence & confidence

The direct financial impact of tariffs and the negative market sentiment support a cautious outlook. The company's earnings decline aligns with bearish sentiment, indicating a probable short-term price decrease.

Market effects

Potential negative impact on the manufacturing and retail sectors due to increased costs and profit pressures.

Possible regional economic slowdown in areas with high manufacturing activity.

Limited, as the impact is primarily on a specific company and sector.

Counterpoint

The company may adapt by increasing prices or sourcing alternatives, mitigating profit loss.

Key entities

  • Weyco Group

    A Glendale-based shoe manufacturer facing tariff-related costs.

  • Trump administration

    Imposed tariffs affecting import costs for companies like Weyco Group.

Related articles

$WEYSMed

Weyco Group (WEYS) Q2 2026 Earnings Call Transcript

Weyco Group (WEYS) reported Q2 2026 net sales of $62.2 million, up 7%, and net earnings of $13.3 million. Diluted EPS was $1.39 versus $0.24 a year earlier, helped by $15.3 million tariff refunds recognized after the U.S. Supreme Court invalidated certain tariffs. Wholesale net sales rose 7% to $48.8 million; cash was $98.1 million with no debt.

$WEYSMed

Weyco Group, Inc. Q2 2026 Earnings Call Summary

Weyco Group, Inc. reported Q2 2026 results boosted by $15.3 million in tariff refunds after a U.S. Supreme Court ruling invalidated prior IEEPA levies, plus 7% wholesale growth led by Florsheim. Management plans to raise inventory to about $70 million by year-end amid tariff uncertainty, including incremental tariffs of 12.5% on imports from China, Dominican Republic and Vietnam.

$WEYSMed

WEYCO GROUP INC (WEYS): Results of Operations and Financial Condition

WEYCO GROUP INC (WEYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 WEYCO REPORTS SECOND QUARTER 2026 RESULTS ​ ​ Milwaukee, Wisconsin---August 4, 2026---Weyco Group, Inc. (NASDAQ: WEYS) (“we,” “our,” “us” and the “Company”) today announced financial results for the quarter ended June 30, 2026. ​ Second Quarter 2026 Overview ● Net sa

$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi